Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006-2008

Diabetic Medicine

Volumn 31, Issue 6, 2014, Pages 640-646

  Jones, N R V ^a   Fischbacher, C M ^b   Guthrie, B ^c   Leese, G ^d   Lindsay, R S ^e   Mcknight, J A ^f   Pearson, D ^g   Philip, S ^g   Sattar, N ^e   Wild, S H ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b INFORMATION SERVICES DIVISION   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d NINEWELLS HOSPITAL   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f WESTERN GENERAL HOSPITAL   (United Kingdom)

^g UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ANTIDIABETIC AGENT;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIMARY PREVENTION; RISK ASSESSMENT; RISK REDUCTION; SMOKING; UNITED KINGDOM; VERY ELDERLY; AGE DISTRIBUTION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; MULTIVARIATE ANALYSIS; SCOTLAND; SEX RATIO;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SCOTLAND; SEX DISTRIBUTION;

EID: 84900820780     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12409     Document Type: Article

References (29)

1. Bertoni A, Goff D. Diabetes and cardiovascular disease. In: Narayan K, Gregg E, Cowie C eds. Diabetes Public Health. Oxford: Oxford University Press, 2011: 173-194.
2. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
3. Wild S, Macleod F, McKnight J, Watt G, Mackenzie C, Ford I et al. Impact of deprivation on cardiovascular risk factors in people with diabetes: an observational study. Diabet Med 2008; 25: 194-199.
4. Connolly V, Unwin N, Sherriff P, Bilous R, Kelly W. Diabetes prevalence and socioeconomic status: a population-based study showing increased prevalence of type 2 diabetes mellitus in deprived areas. J Epidemiol Community Health 2000; 54: 173-177.
5. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of 'statin' lipid-lowering drugs compared with guidelines. Arch Intern Med 2001; 161: 53-58.
6. Simpson CR, Hannaford PC, Williams D. Evidence for inequalities in the management of coronary heart disease in Scotland. Heart 2005; 91: 630-634.
7. Ashworth M, Lloyd D, Smith RS, Wagner A, Rowlands G. Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'. J Public Health (Oxf) 2007; 29: 40-47.
8. Joint British Societies. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91: v1-52.
9. Network Scottish Intercollegiate Guidelines. SIGN 55 Management of Diabetes. Edinburgh: SIGN, 2001.
10. Thomsen RW, Johnsen SP, Olesen AV, Mortensen JT, Bøggild H, Olsen J et al. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005; 60: 534-542.
11. Ohlsson H, Lynch K, Merlo J. Is the physician's adherence to prescription guidelines associated with the patient's socio-economic position? An analysis of statin prescription in South Sweden. J Epidemiol Community Health 2010; 64: 678-683.
12. Jackson CA, Jones NRV, Walker JJ, Fischbacher CM, Colhoun HM, Leese GP et al. Area-based socioeconomic status, type 2 diabetes and cardiovascular mortality in Scotland. Diabetologia 2012; 55: 2938-2945.
13. McKnight JA, Morris AD, Cline D, Peden N, Fischbacher C, Wild S. Implementing a national quality assurance system for diabetes care: the Scottish Diabetes Survey 2001-2006. Diabet Med 2008; 25: 743-746.
14. The Scottish Government. SIMD Methodology. Edinburgh: The Scottish Government, 2006. Available at http://www.scotland.gov.uk/Resource/Doc/933/0063165.pdf Last accessed 4 March 2014.
15. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
16. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.
17. Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007; 115: 700-707.
18. DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Cook DG. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 2003; 89: 417-421.
19. Gaw A. The care gap: underuse of statin therapy in the elderly. Int J Clin Pract 2004; 58: 777-785.
20. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. J Am Med Assoc 2004; 291: 1864-1870.
21. Hart JT. The inverse care law. Lancet 1971; 1: 405-412.
22. Beard AJ, Hofer TP, Downs JR, Lucatorto M, Klamerus ML, Holleman R et al. Assessing appropriateness of lipid management among patients with diabetes mellitus: moving from target to treatment. Circ Cardiovasc Qual Outcomes 2013; 6: 66-74.
23. Tunstall-Pedoe H, Woodward M. By neglecting deprivation, cardiovascular risk scoring will exacerbate social gradients in disease. Heart 2006; 92: 307-310.
24. Dixon A, Khachatryan A, Gilmour S. Does general practice reduce health inequalities? Analysis of quality and outcomes framework data. Eur J Public Health 2012; 22: 9-13.
25. MacBride-Stewart SP, Elton R, Walley T. Do quality incentives change prescribing patterns in primary care? An observational study in Scotland. Fam Pract 2008; 25: 27-32.
26. Selmer R, Sakshaug S, Skurtveit S, Furu K, Tverdal A. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. Br J Clin Pharmacol 2009; 67: 355-362.
27. Gnavi R, Migliardi A, Demaria M, Petrelli A, Caprioglio A, Costa G. Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities. Eur J Public Health 2007; 17: 492-496.
28. Serruys PW, Morice M-C, Kappetein AP, Colombo A, Holmes DR, Mack MJ et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: 961-972.
29. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-1516.